Predictors of Erectile Function Normalization in Men With Erectile Dysfunction Treated With Placebo

Area of Science:

• Urology
• Clinical Pharmacology
• Psychology

Background:

• Sildenafil is proven to improve erectile function (ED) in men.
• However, a notable percentage of men in placebo-controlled studies also report improved erectile function.
• This phenomenon, known as the placebo response, requires further investigation.

Purpose of the Study:

• To analyze the relationship between demographic variables and comorbidities with placebo response in men with ED.
• To identify predictors of placebo response in men receiving placebo in sildenafil studies.
• To enhance understanding of factors influencing treatment outcomes in ED clinical trials.

Main Methods:

• Analysis of data from 4,360 men with ED in 42 double-blind, placebo-controlled, flexible-dose sildenafil studies.
• Participants were classified as placebo responders if their International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) score was ≥26 at the last visit.
• Stepwise multivariate logistic regression was used to assess predictors of placebo response.

Main Results:

• 13.5% of participants were placebo responders.
• Black men, those younger than 45, men with mild ED (baseline IIEF-EFD ≥17), and those without diabetes showed a higher likelihood of placebo response.
• Increased ED duration was associated with a decreased likelihood of placebo response.

Conclusions:

• Demographic factors, comorbidities, and condition characteristics significantly predict placebo response in men with ED undergoing sildenafil treatment.
• Identifying these predictors aids in refining clinical trial methodologies and developing targeted treatment strategies.
• Further research is needed to elucidate the underlying mechanisms driving placebo responses in ED.